Chemed Co. (NYSE:CHE) has been assigned an average recommendation of “Hold” from the eight ratings firms that are covering the company, MarketBeat reports. Four analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $236.00.

CHE has been the subject of a number of research analyst reports. Zacks Investment Research lowered Chemed from a “buy” rating to a “hold” rating in a report on Tuesday, September 26th. Royal Bank of Canada reiterated a “hold” rating and set a $209.00 price target on shares of Chemed in a report on Tuesday, October 3rd. KeyCorp reiterated a “hold” rating on shares of Chemed in a report on Friday, October 27th. Oppenheimer upped their price target on Chemed from $220.00 to $225.00 and gave the stock an “outperform” rating in a report on Friday, October 27th. Finally, TheStreet upgraded Chemed from a “c+” rating to an “a-” rating in a report on Friday, October 27th.

Shares of Chemed (NYSE CHE) opened at $261.61 on Wednesday. The stock has a market capitalization of $4,210.00, a P/E ratio of 58.27, a price-to-earnings-growth ratio of 2.94 and a beta of 1.16. The company has a current ratio of 0.50, a quick ratio of 0.48 and a debt-to-equity ratio of 0.15. Chemed has a 12-month low of $163.50 and a 12-month high of $266.31.

Chemed (NYSE:CHE) last announced its earnings results on Thursday, October 26th. The company reported $2.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.00 by $0.15. The firm had revenue of $417.40 million during the quarter, compared to analysts’ expectations of $414.34 million. Chemed had a return on equity of 27.69% and a net margin of 4.62%. The company’s revenue was up 6.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.73 earnings per share. equities analysts forecast that Chemed will post 4.73 EPS for the current fiscal year.

In related news, CEO Kevin J. Mcnamara sold 10,000 shares of the company’s stock in a transaction on Tuesday, October 31st. The stock was sold at an average price of $223.42, for a total value of $2,234,200.00. Following the completion of the transaction, the chief executive officer now directly owns 170,016 shares in the company, valued at $37,984,974.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Michael D. Witzeman sold 1,000 shares of the company’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $250.00, for a total value of $250,000.00. Following the completion of the transaction, the vice president now owns 3,334 shares of the company’s stock, valued at $833,500. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 45,679 shares of company stock valued at $10,628,959. Corporate insiders own 4.90% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the stock. APG Asset Management N.V. acquired a new position in shares of Chemed in the third quarter valued at $5,657,000. Cabot Wealth Management Inc. raised its stake in shares of Chemed by 4.1% in the third quarter. Cabot Wealth Management Inc. now owns 18,062 shares of the company’s stock valued at $3,649,000 after purchasing an additional 715 shares in the last quarter. Municipal Employees Retirement System of Michigan raised its stake in shares of Chemed by 56.6% in the third quarter. Municipal Employees Retirement System of Michigan now owns 6,030 shares of the company’s stock valued at $1,218,000 after purchasing an additional 2,180 shares in the last quarter. Pinebridge Investments L.P. raised its stake in shares of Chemed by 66.6% in the second quarter. Pinebridge Investments L.P. now owns 3,544 shares of the company’s stock valued at $725,000 after purchasing an additional 1,417 shares in the last quarter. Finally, ClariVest Asset Management LLC raised its stake in shares of Chemed by 9.2% in the third quarter. ClariVest Asset Management LLC now owns 21,655 shares of the company’s stock valued at $4,375,000 after purchasing an additional 1,827 shares in the last quarter. Institutional investors and hedge funds own 97.71% of the company’s stock.

WARNING: “Chemed Co. (CHE) Given Consensus Recommendation of “Hold” by Brokerages” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.americanbankingnews.com/2018/01/17/chemed-co-che-given-consensus-recommendation-of-hold-by-brokerages.html.

About Chemed

Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.